Tumour necrosis factor-α (TNFα) is a mediator of reactive oxygen species, which are implicated in endothelial dysfunction and atherosclerosis. Type II diabetes is associated with endothelial dysfunction and elevated circulating TNFα. We hypothesized that reducing serum levels of TNFα, using pentoxifylline, would improve endothelial function. Thirteen subjects [age 58p2 (S.E.M.) years] with Type II diabetes (disease duration 74p13 months) undertook a randomized, crossover study of 8 weeks pentoxifylline and 8 weeks placebo. Endothelium-dependent and -independent vasodilation in resistance arteries was assessed via bilateral forearm venous occlusion plethysmography during intra-brachial infusions of acetylcholine (ACh), sodium nitroprusside (SNP) and N G -monomethyl-L-arginine (L-NMMA). High-resolution ultrasound of the brachial artery in response to ischaemia was used to determine endothelium-dependent conduit vessel flow-mediated dilation (FMD), and endothelium-independent conduit function was assessed by sublingual administration of glyceryl trinitrate (GTN). Serum concentrations of TNFα were also determined. Pentoxifylline lowered serum TNFα from 4.1p0.7 to 2.9p 0.6 pg : ml − 1 (P l 0.001). Forearm blood flow (FBF) responses at each dose of ACh did not differ with treatment (P l 0.4). Similarly, FBF responses to SNP (P l 0.8) and L-NMMA (P l 0.2) did not differ. There was also no significant difference in brachial artery diameter during FMD (P l 0.2) or GTN administration (P l 0.06). Despite lowering serum TNFα concentration, pentoxifylline at a dose of 400 mg three times a day for 8 weeks did not improve vascular function in either conduit or resistance vessels in this group of Type II diabetic subjects.
INTRODUCTION
Endothelial dysfunction is associated with risk factors for atherosclerosis, appears to be an early manifestation of this disease [1] , and can be regularly documented in the found to have endothelial dysfunction [7] [8] [9] , which can be improved by some intervention [10] [11] [12] .
Endothelial dysfunction is associated with reduced bioavailability of endothelium-derived nitric oxide (NOd), which has vasodilatory, antiproliferative and antithrombotic properties [13] . It is now recognized that reduced bioavailability of NOd may be due to enhanced quenching, particularly by superoxide anions (O d # ) [14, 15] . Hyperglycaemia, insulin resistance and dyslipidaemia, features of Type II diabetes, have all been associated with increased oxidative stress [14, [16] [17] [18] [19] and are known to impair endothelial function [20] . Therefore, it has been suggested that increased oxidative stress may be an important link between the metabolic syndrome that accompanies diabetes and endothelial dysfunction [21] .
The primary source of oxidative stress in the vascular wall are O d # ; O d # are principally derived from membranebound NADH oxidase present in endothelial [22] and vascular smooth muscle cells [23] . Tumour necrosis factor-α (TNFα), a potent pro-inflammatory cytokine, stimulates this enzyme to generate sustained amounts of O d # [24] . Administration of TNFα impairs endothelial function in rats [25] , and a number of studies have identified elevated concentrations of TNFα in the plasma of patients with diabetes compared with controls [26] [27] [28] . Furthermore, animal studies indicate that inhibition of the biological activity of TNFα improves vascular function, in part through endothelium-dependent mechanisms [29] . The purpose of the present study was to determine whether pentoxifylline, an agent which inhibits the production of TNFα [30] , improves conduit or resistance vessel endothelial function in Type II diabetic subjects in vivo.
METHODS

Subjects
Thirteen subjects (10 male, 3 female), mean age 58p2 years (meanpS.E.M.), with Type II diabetes and without evidence of microvascular or macrovascular complications were studied. They undertook a screening program consisting of a medical history and examination, haematological and biochemical profile, including measurement of blood glucose, glycated haemoglobin, serum electrolytes, urea and creatinine, uric acid, liver function and serum lipids. The following were excluded : smokers, those with renal impairment or proteinuria, hepatic impairment, more than mild hypercholesterolaemia or hypertension. In addition, those taking medications known to influence vascular function, with the exception of lipid-lowering and conventional diabetic therapies, were also excluded. Of the 13 subjects, six were taking lipid-lowering therapy and nine were taking oral hypoglycaemic agents (three sulphonylurea, three metformin and three combined therapy). None of the subjects were taking aspirin and medication regimes did not alter over the course of the study. No subject had significant retinopathy at full-field photography. The average time from diagnosis of diabetes was 74p13 months. The mean glycated haemoglobin at entry was 7.7p0.4 % (normal range : 6.0 %), indicating moderate glycaemic control. The mean body mass index for the group was 28.9p 1.2 kg : m −# indicating borderline obesity. The study protocol was approved by Royal Perth Hospital Ethics Committee and all subjects gave their written, informed consent.
Study design
The effect of 8 weeks of TNFα lowering therapy was studied using a randomized, double-blind, placebocontrolled crossover protocol of pentoxifylline 400 mg three times a day (Hoechst Marion Roussel, Australia) or similarly packaged placebo. Resistance and conduit vessel function were assessed after 8 weeks, following which crossover occurred, with re-assessment 8 weeks later. In individual subjects, the initial and repeat studies were conducted at the same time of the day. Subjects were required to refrain from eating and drinking, except for water, for 8 h before the procedures. At each visit, a blood sample was taken for biochemical and haematological analysis. No adverse side effects were encountered during the study.
Vascular function assessment
Resistance vessel function
Resistance vessel function was assessed using venous occlusion plethysmography. Investigations were conducted in a quiet laboratory with subjects lying supine. Their arms were raised and supported so that their elbows were approximately at mid-chest. Under local anaesthesia with 2 ml of 1% (w\v) lignocaine (Delta West, Bentley, Western Australia), a 20 gauge arterial cannula (Arrow, Reading, PA, U.S.A.) was introduced into the brachial artery at the cubital fossa of the nondominant arm. A pressure transducer was connected (Transpac, Abbot Laboratories, IL, U.S.A.), and 0.9 % saline infused (30 ml : h −" ) to maintain patency. The cannula provided continuous arterial pressure monitoring, allowed drug infusions via a constant rate infusion pump (Graseby 3400 ; Graseby Medical Ltd, Herts., U.K.) and sampling of arterial blood. Sizematched strain-gauges connected to Hokanson EC4 amplifiers (D E Hokanson Inc., WA, U.S.A.) were placed around both forearms at the point of maximum circumference. Pneumatic pressure cuffs were placed around the wrists and connected to a pressure-regulated air source. Similar cuffs were placed around the upper arms and connected to a Hokanson E20 rapid inflation device.
After a 25 min rest period, 5 min of baseline measurements were recorded. Immediately prior to each set of forearm blood flow (FBF) measurements, the wrist cuffs were inflated to 200 mmHg to eliminate blood flow to the hands. During recordings, the upper-arm cuffs were rapidly inflated to 50 mmHg for the first 10 s of every 15 s interval. Graded doses of acetylcholine (ACh ; Miochol-Ciba Vision, Castle Hill, NSW, Australia) were administered at 10, 20 and 40 µg : min −" for 3 min each, followed by sodium nitroprusside (SNP ; David Bull Laboratories, Mulgrave, VIC, Australia) at 2, 4 and 8 µg : min −" , each for 3 min. Lastly, N G -monomethyl-Larginine (L-NMMA ; Clinalfa AG, Switzerland) was infused at 2, 4 and 8 µmol : min −" for 5 min each. There was at least a 15 min rest between drugs and baseline measurements were recorded before each drug infusion. All solutions were prepared aseptically from sterile stock solutions or ampoules immediately before infusion into the brachial artery.
FBF measurements were continuously acquired at 40 Hz using a PowerLab 16\s data acquisition system (ADInstruments, NSW, Australia). Data recorded during the last 75 s (final 5 cuff cycles) of each drug dose or rest period were analysed. Further methodological details can be found in our papers published previously [10] [11] [12] 31] .
Conduit vessel function
Conduit vessel assessment occurred on a separate occasion to the resistance vessel studies. Subjects lay supine for 20 min before the first ultrasound scan was recorded. Brachial artery diameter, mean arterial pressure (MAP) and heart rate (HR) were determined at rest, during flowmediated dilation (FMD) induced by reactive hyperaemia, and after administration of glyceryl trinitrate (GTN ; Aventis Pharma, NSW, Australia).
The monitored, non-dominant arm was positioned at an arm-to-torso angle of approx. 80m, with the distal forearm supinated and immobilized by foam supports encompassing the limb. HR was monitored continuously by three-lead ECG and MAP was measured using an automated sphygmomanometer on the contralateral arm (Dinamap, 8100 ; Critikon, Tampa, FL, U.S.A.). The brachial artery was visualized in the distal third of the upper arm, using a 12 MHz multi-frequency, lineararray probe attached to a high-resolution ultrasound machine (Aspen ; Acuson, Mountain View, CA, U.S.A.). The probe was held in a constant stable position for the duration of the study by a stereotactic clamp and its precise location recorded and standardized for the repeat session. Ultrasonic parameters were set to optimize longitudinal, B-mode imaging of the lumen-arterial wall interface. The focus zone was positioned to optimize visualization of the near wall. Once set, operating parameters remained constant throughout each study.
After the initial 20 min stabilization period, baseline scans were recorded over 2 min. A pneumatic cuff placed around the forearm, immediately distal to the humeral epicondyles, was then rapidly inflated to 200 mmHg for 5 min. FMD of the brachial artery, resulting from ischaemia-induced reactive hyperaemia following release of this cuff, provides a measure of endotheliumdependent, largely NOd-mediated, vasodilation [32] . Bmode recording commenced 30 s before cuff deflation and continued for 2.5 min.
After a rest period of 10 min, when the brachial artery diameter had returned to baseline levels, a second baseline scan was recorded. This was followed by sublingual administration of GTN (400 µg), which provides an index of endothelium-independent dilation.
Analysis of brachial artery diameter was performed using custom-designed edge-detection and wall-tracking software which is independent of investigator bias. Briefly, videotaped images were captured to computer memory at 25 Hz, using a digital frame grabber. ECGgated B-mode frames were then assessed by automated edge detection software which employs a pixel density and frequency distribution algorithm [33] . Images which coincided with the peak of R-waves were analysed, with approx. 100 individual diameter measurements along the artery being averaged per image. A polynomial regression was then fitted to these diameter measurements obtained from successive R-waves. FMD and GTN values were calculated as percentage changes from preceding baseline data.
Biochemical and haematological measurements
TNFα was measured using a commercially available, chemiluminescent enzyme immunometric assay (Immulite ; Bio-Mediq DPC, Doncaster, VIC, Australia). Other biochemical and haematological measurements were carried out by routine methods.
Analysis
An investigator blinded with respect to subject identification analysed all blood flow measurements. Although the low doses of drugs infused in the study produce negligible systemic effects and showed no effect on blood pressure or HR, it is still desirable to account for any possible variation in overall haemodynamics as a cause of the flow changes seen in the infused forearm. Thus, FBF was measured simultaneously in both arms, although only one arm was infused, and the non-infused arm served as a control. Absolute FBF is expressed in units of ml : 100 ml of forearm −" : min −" . However, as in earlier studies [10, 31] , FBF is described as the ratio of FBF in the infused arm to that in the non-infused arm. Changes in these ratios during ACh, SNP and L-NMMA infusions are expressed as percentage changes from the baseline immediately preceding each drug administration [34] .
The responses to intrabrachial infusions after pentoxifylline were compared with placebo responses using one-way ANOVA with repeated measurements performed on the three dose levels of each of ACh, SNP and L-NMMA. All other comparisons of pentoxifylline and placebo periods, including FMD and GTN responses and all biochemical measurements, were undertaken using Student's paired, two-tailed t tests. Results are expressed as meanspS.E.M. and P 0.05 was considered significant.
RESULTS
Seven of the 13 subjects were randomized to receive pentoxifylline first. Resistance vessel function was not measured in two of the 13 subjects due to an inability to cannulate their brachial artery. One further subject was eliminated from the ultrasound analysis because they received only a limited dose of GTN. There was no effect of the order of randomization on the variables measured so results after pentoxifylline treatment were compared with those after the placebo period irrespective of the order of treatment.
Biochemical and haematological data
In response to pentoxifylline, serum concentrations of TNFα decreased from 4.1p0.7 to 2.9p0.6 pg : ml −" (Table 1) . When comparing pentoxifylline treatment and placebo, there were no significant differences in any of the following biochemical or haematological parameters ; total, high-density lipoprotein or low-density lipoprotein cholesterol, triacylglycerols, plasma glucose, glycated haemoglobin, monocyte count and neutrophil count (Table 1) . MAP and HR at rest, during FMD and during drug infusions at each dose were no different between treatments. TNFα levels during placebo in the studied group were not different to those of a group of ten age-and sex-matched non-diabetic control subjects (4.1p0.7 versus 3.4p0.4 pg : ml −" respectively ; P l 0.4).
Forearm resistance vessel function
Baseline FBF in the infused limb, prior to infusion of ACh, did not differ significantly between placebo and treatment with pentoxifylline (2.6p0.2 versus 2.3p 0.3 ml : 100 ml of forearm −" : min −" ). Similarly, absolute FBF responses to graded infusions of ACh (P l 0.5), SNP (P l 0.3) and L-NMMA (P l 0.9) did not differ Tumour necrosis factor-α and endothelial function in diabetes significantly, at any dose, between placebo and pentoxifylline treatment (Table 2) , and there was no interaction between treatment and dose for any infused drug. When data were presented as the percentage change in the ratio of infused to non-infused arm flows, relative to a similar preceding baseline ratio, there were also no significant differences in response to ACh (P l 0.4), SNP (P l 0.8) or L-NMMA (P l 0.2), nor were there any significant interactions between drug dose and study treatment (Table 3) . There was no significant difference in mean blood pressure at any given time point during the protocol. The responses were not dependent on the order of treatment; there was no difference between the placebo data in those who received pentoxifylline first or second, indicating that there was no carry over effect of pentoxifylline in those treated first.
Forearm conduit vessel function
Baseline brachial artery diameters immediately preceding FMD and GTN did not significantly differ between placebo and pentoxifylline administration (Table 4) . FMD in the brachial artery, predominantly a measure of endothelium-dependent vasodilation in conduit vessels, did not differ significantly between placebo and pentoxifylline (6.7p1.9 versus 8.3p1.6 %, Table 4 ). The responses to sublingual GTN administration after pentoxifylline also did not differ significantly from that of placebo (14.0p1.9 versus 11.9p2.8 % respectively, Table 4 ).
DISCUSSION
This is the first study to examine the effect, on endothelial function in humans, of an intervention which lowers circulating TNFα concentration. In this study, pentoxifylline administered in a typical clinical dose significantly decreased the concentration of total TNFα in the serum of adults with Type II diabetes. Despite this effect, endothelium-dependent and -independent vascular function remained unaltered in both resistance and conduit arteries after 8 weeks of therapy with pentoxifylline.
Evidence supporting the concept that endothelial dysfunction may be produced by TNFα is based largely upon in vitro and animal studies. TNFα can stimulate the generation of O d # via activation of NADH oxidase [24] which could diminish NOd bioactivity [13] . Indeed, Lefer et al. [35] reported that ACh-mediated endotheliumdependent relaxation of isolated aortic rings from cats, was impaired in the presence of TNFα. In addition, Wang et al. demonstrated that the administration of TNFα to rats can induce endothelial dysfunction [25] , that pentoxifylline reduces plasma TNFα [36] , and that the impaired endothelial function associated with elevated TNFα [37] is improved by pentoxifylline [38] . Collectively, these studies suggest down-regulation of TNFα as a possible mechanism for the improvement in endothelial function observed with pentoxifylline.
In the present study, there are several possible explanations for the lack of effect of pentoxifylline on endothelial function, despite its significant lowering of the serum TNFα concentration. The latter was, on the average, higher compared with that of a normal non-diabetic subject group, but not significantly so. Perhaps much higher TNFα levels must be present to greatly affect endothelial function. In the study of incubated cat aortic rings, the effect of TNFα was dose-dependent and µg : ml −" , rather than pg : ml −" , concentrations were required to induce depression of endothelial function [35] . In addition, animal studies indicating that pentoxifylline can improve endothelial function were performed on a model of sepsis [38] which is associated with markedly enhanced TNFα production and much higher circulating levels [39] than studies have typically found in obese insulin-resistant subjects in whom TNFα is putatively derived from adipocytes [40] .
Another possible explanation for the lack of effect of lowering TNFα in the present study relates to the body composition of our subjects. Previous studies which have reported increased circulating TNFα in insulin-resistant subjects, in fact, found it to be clearly related to obesity [26] [27] [28] [40] [41] [42] [43] [44] [45] . For example, Nilsson et al. [27] reported that TNFα concentrations correlated with the body mass index in combination with the degree of insulin resistance. Katsuki et al. [26] found serum levels of TNFα to be elevated in Type II diabetic subjects with visceral obesity but not in non-obese diabetic subjects. In contrast to these studies, our subjects were overweight but not clearly obese and, incidentally, there was no significant relationship between the serum TNFα and body mass index, although the ranges of both were small. Finally, the Type II diabetic subjects studied here did not have clearly abnormal endothelial function ; 60 healthy middle-aged subjects we recently studied had a mean FMD of 7.1p0.6 (S.E.M.) %, compared with a value of 6.7p1.9 % in the subjects studied here (P l 0.77). However, our intention in the present study was to determine whether lowering TNFα improves endothelial function in a group of typical diabetic subjects. It is also pertinent that some interventions, such as angiotensin-converting enzyme inhibition [46] , lipid-lowering therapy [47] and exercise training [48] , have been reported to improve endothelial function even in subjects with normal function.
In conclusion, pentoxifylline at a dose of 400 mg three times a day for 8 weeks did not improve vascular function in either conduit or resistance vessels in the group of Type II diabetic subjects in the present study. This negative study does not, however, exclude the possibility that TNFα could be important in contributing to endothelial dysfunction in more severe, or more obese, diabetic subjects.
